Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most musculoskeletal safety statements (myopathy/rhabdomyolysis, symptom reporting, risk factors, and some interaction/dose concepts) are broadly consistent with the label excerpts, but several claims are either not supported by the provided label text (e.g., “yoga-related,” specific symptom/behavioral impacts) or overgeneralize beyond what the label excerpts explicitly state (e.g., persistence guidance and descriptions of dark urine and emergency status).
Category Scores
Accurate Statements
A history of renal impairment may be a risk factor for the development of rhabdomyolysis.
Warnings and Precautions (5.1): “A history of renal impairment may be a risk factor for the development of rhabdomyolysis.”
Atorvastatin can cause myopathy defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN.
Warnings and Precautions (5.1): “Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values >10 times ULN.”
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and with other drugs in this class.
Warnings and Precautions (5.1): “Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported…”
The concomitant use of higher doses of atorvastatin with certain drugs (e.g., cyclosporine and strong CYP3A4 inhibitors such as clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.
Warnings and Precautions (5.1): “The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors… increases the risk of myopathy/rhabdomyolysis.”
Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
Warnings and Precautions (5.1): “Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.”
LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Warnings and Precautions (5.1): “LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.”
LIPITOR is metabolized by CYP3A4; concomitant administration with strong inhibitors of CYP3A4 can increase plasma concentrations of atorvastatin.
Drug Interactions (7.1): “LIPITOR is metabolized by cytochrome P450 3A4. Concomitant administration… can lead to increases in plasma concentrations of atorvastatin…”
In patients taking cyclosporine, therapy should be limited to LIPITOR 10 mg once daily.
Dosage and Administration (2.6): “In patients taking cyclosporine, therapy should be limited to LIPITOR 10 mg once daily.”
In patients taking clarithromycin/itraconazole or certain HIV protease inhibitors, caution is used when the LIPITOR dose exceeds 20 mg.
Dosage and Administration (2.6): “for doses of LIPITOR exceeding 20 mg, appropriate clinical assessment is recommended…” and Drug Interactions (7.1): “Therefore, in patients taking clarithromycin… caution should be used when the LIPITOR dose exceeds 20 mg…”
Unsupported Statements
Lipitor (atorvastatin) can cause muscle side effects in some people.
While the label supports muscle aches/weakness/myopathy and rhabdomyolysis, the provided excerpts do not explicitly contain the exact phrasing “can cause muscle side effects in some people.”
Statins like atorvastatin can cause muscle side effects ranging from mild aches to rarer, more serious muscle injury.
Label excerpt describes myopathy (muscle aches/weakness) and rare rhabdomyolysis, but does not explicitly characterize a spectrum from mild to rare serious in the provided text.
Lipitor does not specifically target “yoga-related” flexibility.
No discussion in the provided label excerpts regarding yoga, flexibility, or targeted musculoskeletal effects.
Muscle discomfort or weakness may make stretching feel harder or less comfortable.
The label does not discuss stretching or functional impact on stretching comfort.
Common statin muscle issues include muscle pain, tenderness, cramps, or weakness.
The label excerpt explicitly mentions “muscle aches or muscle weakness” and “muscle pain, tenderness, or weakness,” but does not mention cramps in the provided excerpts.
Some people experience a “stiff” feeling as a muscle-related symptom while taking statins.
The provided label excerpts do not mention “stiff” as a symptom.
Statin muscle symptoms can limit how far a person wants to stretch even if joints are fine.
No statement in the provided label excerpts about stretching limitations or joint-specific considerations.
Rhabdomyolysis can cause dark urine.
The provided label excerpt states rhabdomyolysis secondary to myoglobinuria, but it does not explicitly mention “dark urine.”
Rhabdomyolysis is a medical emergency.
The label excerpt does not explicitly call rhabdomyolysis a medical emergency.
Risk of muscle problems with statins can be higher with higher statin doses.
The label excerpt supports increased risk with “concomitant use of higher doses of atorvastatin with certain drugs,” but it does not broadly state dose alone increases risk.
Risk of muscle problems with statins can be higher in people with other medical conditions that affect muscle health.
The label excerpt does list acute serious conditions and risk factors related to renal failure secondary to rhabdomyolysis, but does not broadly support this generalized statement as written.
Muscle symptoms that begin soon after starting Lipitor (or after dose increases) are more suggestive of a medication-related muscle effect.
The label excerpt does not provide a time-course or “soon after starting/dose increases” rationale.
New or worsening muscle pain or weakness that persists while taking Lipitor warrants contacting a clinician.
The label excerpt advises reporting promptly unexplained muscle pain/tenderness/weakness, and states discontinuation if myopathy suspected/CPK markedly elevated, but does not include “persists while taking” or the specific instruction to contact a clinician as framed.
Muscle symptoms that are spreading or severe while taking Lipitor warrant contacting a clinician.
The label excerpt does not mention “spreading” or provide criteria framed as contacting a clinician for spreading/severe symptoms.
Dark-colored urine while taking Lipitor warrants contacting a clinician.
Label excerpt does not explicitly mention dark-colored urine or that specific instruction.
Fever while taking Lipitor warrants contacting a clinician.
The label excerpt mentions reporting muscle pain/tenderness/weakness particularly if accompanied by malaise or fever, but does not provide the standalone directive “Fever… warrants contacting a clinician.”
Feeling very unwell while taking Lipitor warrants contacting a clinician.
The label excerpt mentions reporting muscle symptoms particularly if accompanied by malaise or fever; it does not provide the standalone statement.
Significant muscle injury from statins requires urgent evaluation.
The label excerpt does not explicitly use “urgent evaluation” wording.
A prescriber may check labs, often including creatine kinase, if muscle symptoms are present.
The label excerpt defines myopathy with CPK >10x ULN and mentions markedly elevated CPK levels but does not state that labs “often including creatine kinase” are checked for symptoms.
A prescriber may adjust the dose of Lipitor if muscle symptoms occur.
The label excerpt states LIPITOR should be discontinued if myopathy diagnosed or suspected or markedly elevated CPK occurs; it does not state dose adjustment as an option for muscle symptoms.
A prescriber may switch to another statin if muscle symptoms occur.
No statement in the provided excerpts about switching to another statin.
Patients should not stop Lipitor on their own without medical advice.
The provided label excerpts do not include this patient instruction.
A cardiovascular benefit is important for many people on Lipitor.
While the label excerpt includes cardiovascular risk reduction outcomes, it does not state “important for many people” in the provided text.
If muscle symptoms are mild and addressed (for example, dose adjustment or switching therapy), many people can resume normal activity.
The provided label excerpts do not discuss resuming normal activity, or “mild symptoms” management, or dose adjustment/switching as a route back to normal activity.
Contradictions
Important Omissions
Clear label-aligned instruction that LIPITOR therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.
Importance:
High
Specific contraindication information (active liver disease, hypersensitivity, pregnancy, nursing) was not addressed.
Importance:
Moderate
Label monitoring recommendation for liver function tests (prior to and at 12 weeks after initiation and dose increases, periodically thereafter) was omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several key label-consistent points about myopathy/rhabdomyolysis and reporting muscle symptoms are present, but multiple claims introduce unsupported specifics (e.g., dark urine phrasing, emergency status, time-course) and omit explicit label-required discontinuation guidance for suspected myopathy/marked CPK elevations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Overgeneralized/unsupported symptom descriptions and management instructions (e.g., dark urine, emergency language, dose adjustment/switching therapy, resuming activity) and omission of explicit label discontinuation/CPK-based guidance.
Suggested Improvement
Remove or qualify unsupported symptom/functional and time-course claims; align management language to the label excerpt (report promptly; consider CPK; discontinue if markedly elevated CPK or myopathy diagnosed/suspected; recognize listed risk factors and drug-interaction/dose limits for CYP3A4 inhibitors and cyclosporine).